Clinical trial
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre, Double-Blind, Randomised Controlled Trial (ESCaMS Trial)
NCT07770282 is registered in ClinicalTrials.gov with All India Institute of Medical Sciences, Bhubaneswar as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre, Double-Blind, Randomised Controlled Trial (ESCaMS Trial)
- Lead sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 30, 2030
- Enrollment
- 600 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
antipsychotic-induced weight gain, cardiovascular risk, insulin resistance, metabolic syndrome, schizophrenia disorder